Novavax, Inc.’s Phase III trial of NVX–CoV2373 COVID-19 vaccine candidate demonstrated final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain in the UK trial. The company completed analysis of its Phase 2b trial in South Africa, with efficacy of 55.4% among the HIV- negative trial participants in a region where the vast majority of strains are B1.351 escape variants. Across both trials, NVX-CoV2373 demonstrated 100% protection against severe dise...